Keyword: Ultomiris (ravulizumab-cwvz)
With its campaign to switch patients from blockbuster Soliris to Ultomiris going well, Alexion is swinging for the fences with a late-stage ALS study.
Alexion is facing a competitor to its blockbuster Soliris amid a switching campaign to a follow-up drug. But analysts so far aren't concerned.
Alexion, amidst a strategy shift to pipeline building, has said no to an activist investor's call to pursue a "proactive" sale.
Alexion is working to switch patients from Soliris to its newer Ultomiris.
Alexion is pushing hard to get patients on its blockbuster Soliris over to a follow-up drug, but the older med's sales are still hanging in there.
Alexion's campaign to switch patients from blockbuster Soliris to a follow-up drug has gone according to plan. A new indication will help even more.
Investors are running scared after a patent challenge from Amgen hit Alexion’s bestselling Soliris—but is it that big of a deal?
9. Alexion Pharmaceuticals
Rumors that Amgen could buy Alexion have been floating around for more than a year. Now, they’ve resurfaced, to the delight of Wall Street analysts.
Alexion's plan to switch patients from blockbuster Soliris to newcomer Ultomiris in on track. But why isn't the company's share price reflecting that?